▶주메뉴 바로가기
▶본문 바로가기
[THE INVESTOR] Boryung Pharmaceutical said on Aug. 10 it has become the biggest shareholder of Korea’s immune cell therapy developer Vigencell in a bid to diversify its drug pipeline. Boryung now o...
[THE INVESTOR] A demand from Celltrion 's minority shareholders to move the company’s stock to the benchmark KOSPI market from the secondary KOSDAQ is expected to have a limited impact on restrain...
[THE INVESTOR] Dong-A Socio Holdings Chairman Kang Jung-seok was arrested on Aug. 8 for allegedly offering kickbacks to local hospitals and evading taxes. The Busan District Court issued a warrant ...
[THE INVESTOR] Korean drug makers are looking to roll out generic versions of Pfizer’s smoking cessation medication Champix to heat up the competition. Champix has been dominating the market on the...
[THE INVESTOR] A team of Korean scientists has recently found a clue to preventing one of the most horrifying fears of surgery patients, being awake during surgery, according to POSTECH on Aug. 4. ...
[THE INVESTOR] Medytox’s plan to launch its liquid-type botullinum toxin in the US may be delayed again as its partner Allergan is cagey about the drug’s further development. Allergan, which in-lice...
[THE INVESTOR] Korean scientists from the Daejeon-based Institute for Basic Science have contributed to safely repairing a disease-causing mutation in human embryos via gene-editing technology, mark...
[THE INVESTOR] Korea’s Ministry of Food and Drug Safety said on Aug. 3 it has approved the country’s first surgical robot Revo-i, which facilitates complex surgery using a minimally invasive approac...
[ THE INVESTOR ] LG Chem said on Aug. 2 that South Korea’s Ministry of Food and Drug Safety had approved Zemiro, a combination drug that simultaneously treats diabetes and dyslipidemia, a conditi...
[THE INVESTOR] Korean drug maker Yungjin Pharm said on Aug. 2 that it completed phase 2a clinical trials of its new lung treatment candidate YPL-001 in the US, sending its shares sharply up. YPL-00...
[THE INVESTOR] Celltrion 's Truxima, its copy version of Roche’s top-selling treatment Mabthera, has achieved rapid market penetration in some European countries, the company’s marketing affiliate ...
[THE INVESTOR] Sanofi on Aug. 1 confirmed that the French drug maker will conduct a late-stage clinical study on a diabetes treatment candidate developed by Korea’s Hanmi Pharmaceutical during the f...
[THE INVESTOR] Celltrion said on July 31 that the US Food and Drug Administration has accepted the firm’s license application for Herzuma, its biosimilar copy of Roche’s blockbuster breast cancer t...
[ THE INVESTOR ] The medical community is reeling from the planned minimum wage hike next year, with small neighborhood clinics and hospitals appealing for at least a matching hike in billing rates...
[THE INVESTOR] Korean biotech firm Cellumed said on July 28 that it has filed a patent application for a new substance for developing longer lasting dermal fillers that are injected beneath the sk...
SK hynix may be far from acquiring Toshiba
LG to build EV-parts factory in US
SK Planet mulls exit from Indonesia
Korean mobile games still shut out of China
Hyundai Santa Cruz gets green light for production
Celltrion could attract W300b with KOSPI relisting
FTC chief urges Hyundai to tackle governance structure
Samsung Galaxy Note 8 ditches ATL batteries
